RE:ASCO 2024 - Trial in Progress abstracts Trials in Progress posters provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. In addition, Trials in Progress highlight the transition of emerging biologic pathways and new agents into the clinic—providing "coming attractions" for oncologists in clinical practice.
https://conferences.asco.org/am/trials-progress-abstract-submission-guidelines
Preceeding and in concert with ONCY presentation at ASCO 2024 - May 31 - June 4, 2024, is ONCY's Type C Meeting with the FDA that is seeking alignment with the FDA on the use of clinically identified biomarkers and conventional surrogate endpoints of ORR, PFS and OS to drive the accelerated approval of pelareorep in an expanded HER2 failed breast cancer population of patients, that includes all patients from early stage to late stage metastatic breast cancer, who have failed both estrogen and ADC therapy, and where a significant "unmet treatment need" exists.
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=36047891